These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33497609)

  • 61. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
    Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
    Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation.
    Zarei S; Leuba F; Arrighi JF; Hauser C; Piguet V
    J Allergy Clin Immunol; 2002 Jun; 109(6):988-94. PubMed ID: 12063529
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
    Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
    Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector.
    Lee S; Kim YY; Ahn HJ
    Biomaterials; 2021 May; 272():120793. PubMed ID: 33836291
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
    Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
    Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
    [TBL] [Abstract][Full Text] [Related]  

  • 66. RNAi/CRISPR Screens: from a Pool to a Valid Hit.
    Schuster A; Erasimus H; Fritah S; Nazarov PV; van Dyck E; Niclou SP; Golebiewska A
    Trends Biotechnol; 2019 Jan; 37(1):38-55. PubMed ID: 30177380
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CRISPR Gene Therapy of the Eye: Targeted Knockout of Vegfa in Mouse Retina by Lentiviral Delivery.
    Holmgaard A; Alsing S; Askou AL; Corydon TJ
    Methods Mol Biol; 2019; 1961():307-328. PubMed ID: 30912054
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Application of Genome Editing Techniques in Immunology.
    Zych AO; Bajor M; Zagozdzon R
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):289-298. PubMed ID: 29344676
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
    Murphy KA; James BR; Guan Y; Torry DS; Wilber A; Griffith TS
    Hum Vaccin Immunother; 2015; 11(7):1612-20. PubMed ID: 25996049
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells.
    Tran J; Kung SK
    Mol Ther; 2007 Jul; 15(7):1331-9. PubMed ID: 17505478
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adoptive immunotherapy using lymphokine-activated killer cells.
    Fowler JE
    J Urol; 1988 Jan; 139(1):148-9. PubMed ID: 3257273
    [No Abstract]   [Full Text] [Related]  

  • 75. Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance.
    Han P; Dai Q; Fan L; Lin H; Zhang X; Li F; Yang X
    Front Immunol; 2019; 10():251. PubMed ID: 30837996
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
    Wang L; Chen Y; Liu X; Li Z; Dai X
    Front Oncol; 2021; 11():704999. PubMed ID: 35111663
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vivo multidimensional CRISPR screens identify
    Ji P; Gong Y; Jin ML; Wu HL; Guo LW; Pei YC; Chai WJ; Jiang YZ; Liu Y; Ma XY; Di GH; Hu X; Shao ZM
    Sci Adv; 2022 Jul; 8(26):eabl8247. PubMed ID: 35767614
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High-content CRISPR screening in tumor immunology.
    Holcomb EA; Pearson AN; Jungles KM; Tate A; James J; Jiang L; Huber AK; Green MD
    Front Immunol; 2022; 13():1041451. PubMed ID: 36479127
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7.
    Wisnovsky S; Möckl L; Malaker SA; Pedram K; Hess GT; Riley NM; Gray MA; Smith BAH; Bassik MC; Moerner WE; Bertozzi CR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495350
    [No Abstract]   [Full Text] [Related]  

  • 80. Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic
    Schmalkuche K; Rother T; Burgmann JM; Voß H; Höffler K; Dogan G; Ruhparwar A; Schmitto JD; Blasczyk R; Figueiredo C
    Front Immunol; 2024; 15():1404668. PubMed ID: 38903492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.